New series of 4,6-diheteroarylpyrimidine-2ـamines (4a-e) and (5a-c) were prepared by cyclization of particular chalcones (2) or (3) with guanidine nitrate in the presence of potassium hydroxide. Chalcones (2) and (3) were prepared by base-catalyzed Claisen-Schmidt condensation of heteroaryl aldehydes (1) with 2-acetyl-5-chlorothiophene and 3-acetyl-2,5-dichlorothiophene, respectively. All the newly synthesized compounds were characterized by spectroscopic and spectrometric techniques such as IR, 1H NMR, 13C NMR and mass spectrometry. This study evaluated in vitro glyoxalase I (GLO-I) inhibitory activity, coupled with molecular docking analysis. Spectroscopic methods confirmed the structures, and structure-activity relationship was established, revealing the importance of chloro substitutions and a furan ring for enhanced inhibition. In vitro glyoxalase inhibitory activity showed that 5b has excellent inhibitory activity against the glyoxalase I enzyme, with an IC50 of 15 µM. Molecular docking using AutoDock 4.2 highlighted key interactions within the active site of the human glyoxalase I enzyme, underscoring the absence of direct Zn interactions in the synthesized compounds compared to the cocrystallized ligand and revealing the need for structural optimization to introduce metal-binding functionalities. This research paves the way for the rational design of more potent glyoxalase I inhibitors, contributing significantly to the field of enzyme inhibition and therapeutic agent development.
No takes yet. Share an insight, caveat, or question.
Ibrahim et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: